Angio-seal VIP Versus Perclose ProGlide for Closure of the Femoral Artery in Peripheral Vascular Disease

Peripheral Vascular Diseases Clinical Trial

Official title:

Angio-seal VIP Versus Perclose ProGlide for Closure of the Femoral Artery in Peripheral Vascular Disease: a Prospective Single-center Randomized Non-inferiority Trial

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05334095
• Other study ID #: 2019-ZX09
• Status: Recruiting
• Phase: N/A
• Start date: August 20, 2019
• Est. completion date: September 1, 2022

Study information

• Verified date: April 2022
• Source: Chinese Academy of Medical Sciences, Fuwai Hospital
• Contact: Xiongjing Jiang, MD
• Phone: +861088322385
• Email: jxj103[@]hotmail.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is designed to evaluate the efficacy (device deployment characteristics and performance) and safety (adverse access site related events) of Perclose ProGlide (Abbott Vascular Devices) for femoral access site closure in patients undergoing peripheral vascular diagnostic and interventional procedures in comparison with Angio-seal VIP (St. Jude Medical).

Description:

Prospective, single-center, randomized (1:1), open-label, non-inferiority study in 1062 patients comparing Perclose ProGlide (test device) to the Angio-seal VIP (standard comparator).

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 1062
• Est. completion date: September 1, 2022
• Est. primary completion date: June 1, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 85 Years

Eligibility

Inclusion Criteria:

• Patient is =18 and < 85 years of age.

• Patient is willing to provide written informed consent prior to study device use.

• Patient is undergoing a peripheral vascular diagnostic and/or interventional procedure via femoral arterial access.

• Patients' arterial puncture site is in the common femoral artery confirmed by a femoral angiogram, and =10mm away from the ostium of the inferior epigastric artery (IEA) and the bifurcation of superficial femoral artery and the profunda femoris artery.

Exclusion Criteria:

• The femoral access site has been punctured within 30 days, or deployed with a collagen-based hemostasis device within 90 days, or a suture-mediated closure device.

• Patients having a hematoma, pseudoaneurysm or arteriovenous fistula present prior to sheath removal confirmed by a femoral angiogram.

• Patients with minimum femoral artery calcium which is fluoroscopically visible at access site or femoral artery diameter stenosis greater than 50%.

• Ankle-brachial index (ABI) of the ipsilateral limb of access site cannot be measured due to severe peripheral artery disease (PAD).

• Patients who are pregnant or lactating.

Related Conditions & MeSH terms

• Percutaneous Intervention Via Femoral Artery
• Peripheral Arterial Disease
• Peripheral Vascular Diseases
• Vascular Diseases

Intervention

Device:
• Perclose ProGlide
After peripheral vascular diagnostic and interventional procedures, patients are randomized to receive Perclose ProGlide.
• Angio-seal VIP
After peripheral vascular diagnostic and interventional procedures, patients are randomized to receive Angio-seal VIP

Locations

Country	Name	City	State
China	Fuwai Hospital, National Center for Cardiovascular Disease, Chinese Academy of Medical Sciences and Peking Union Medical College	Beijing	Beijing

Sponsors (1)

Lead Sponsor	Collaborator
Xiongjing Jiang

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Incidence of the device successfully deployed and absence of the major vascular complications necessitating aggressive treatments (surgical or percutaneous repair etc.) at 30 days	Deployment procedure success is defined as haemostasis after the delivery and release of a closure device, manual compression is no longer needed or less than 5 minutes, and no more closure devices are needed.; Major vascular complications include: Vascular injury related to access site requiring surgical or percutaneous intervention, or ultrasound guided compression, or thrombin injection.; New onset lower extremity ischemia attributed to arterial access or closure, and/or the ABI of the ipsilateral limb of access site decreased by =0.15 or requiring surgical or additional percutaneous intervention.; haemorrhage related to access site requiring transfusion, or haemoglobin decreased by =5g/dl or hematocrit (HCT) decreased by =15%; Infection requiring a hospitalization extended for more than 24 hours or a new hospitalization or treatment with intravenous antibiotics.; Nerve injury related to access site which is permanent or requires surgery.	30 days post procedure
Secondary	Minor ipsilateral access site complications at 30 days and generally no aggressive treatment is required	Minor ipsilateral access site vascular complications included: Access site pseudoaneurysm or AV fistula documented by ultrasound, neither surgical nor percutaneous intervention is required.; Post-discharge access site-related haemorrhage requiring = 30 minutes manual compression to re-achieve hemostasis.; Lower extremity arterial stenosis attributed to arterial access or closure, whereas neither surgical nor percutaneous intervention is required.; haemorrhage related to access site with no transfusion required. while, transfusion is required when haemoglobin decreased by <5g/dl or hematocrit (HCT) decreased by <15%.; Access site hematoma = 6 cm, neither blood transfusion nor surgical intervention is required.; Localized access site infection treated with intramuscular or oral antibiotics.; Transient access site-related nerve injury.	30 days post procedure
Secondary	Incidence at 180 days of the composite endpoint of major vascular complications necessitating aggressive treatments (surgical or percutaneous repair etc.)	Major vascular complications include: Vascular injuries related to access site requiring surgical or percutaneous intervention, or ultrasound guided compression, or thrombin injection.; New onset lower extremity ischemia that is attributed to arterial access or closure, and the ABI of the ipsilateral limb of access site decreased by =0.15 or requiring surgical or additional percutaneous intervention.; Bleeding related to access site requiring transfusion or haemoglobin decreased by =5g/dl or hematocrit (HCT) decreased by =15%; Infection requiring a extended hospitalization for more than 24 hours or a new hospitalization or treatment with intravenous antibiotics.; Nerve injury related to access site is permanent or requires surgery.	180 days post procedure
Secondary	Deployment procedure time	Deployment procedure time was defined as elapsed time from the first skin break to final closure (skin to skin time)	within 24 hours of device deployment
Secondary	Time to haemostasis from removing the sheath until haemostasis	Haemostasis is considered as insignificant bleeding on the bandage or small continuous oozing, manual compression is no longer needed or less than 5 minutes.	within 24 hours of device deployment
Secondary	Patients' comfort level during the deployment of the closure device using the visual analog scale (VAS)	0 cm means no pain, while 10 cm means the worst imaginable pain or the worst pain one had experienced	within 5 minutes of device deployment